AR and breast cancer: Our observation suggests that aspirin and dydrogesterone can target AKR1C1 in BC, and DCIS_adjIDC patients with the TIAM1 amplification‐AR overexpression‐AKR1C1 overexpression axis may be able to receive aspirin or dydrogesterone adjuvant therapy.